ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - April 2015

Decade

Year

Issue

March 2022, Vol 8, No. 3, Pages 326-487

Original Investigation

Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2022;8(3):345-353. doi:10.1001/jamaoncol.2021.6628

This randomized clinical trial of patients with a primary bone tumor or a soft tissue sarcoma compares the effects of a 5-day vs 1-day regimen of postoperative, prophylactic, intravenous antibiotics on surgical site infections within 1 year after surgery.

Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):354-363. doi:10.1001/jamaoncol.2021.6826

This genomic association study evaluates the association of genetic ancestry with childhood acute lymphoblastic leukemia (ALL) molecular subtypes and outcomes of modern acute lymphoblastic leukemia therapy.

Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):364-372. doi:10.1001/jamaoncol.2021.6416

This cohort study summarizes 2-year follow-up of patients with human papillomavirus–associated oropharyngeal carcinoma who received radiotherapy to subclinical regions at a reduced dose and target volume of 30 Gy.

Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):374-382. doi:10.1001/jamaoncol.2021.6720

This study compares the 2021 US Preventive Services Task Force lung cancer screening criteria with other lung cancer screening criteria and evaluates whether the sensitivity and specificity of these criteria differ by race.

Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis

Abstract Full Text
free access has audio
JAMA Oncol. 2022;8(3):385-392. doi:10.1001/jamaoncol.2021.6818

This prognostic study assesses whether a signature on computed tomographic imaging derived from tumor size, density, and shape and its change as treatment is administered can estimate overall survival in patients with advanced melanoma.

Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer Survivors

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):395-403. doi:10.1001/jamaoncol.2021.6590

This prospective cohort examines independent and joint associations of daily sitting time and physical activity with mortality outcomes among a nationally representative sample of cancer survivors during more than 4 years of follow-up.

Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):404-411. doi:10.1001/jamaoncol.2021.6846

This cohort study of adults with myelodysplastic syndrome assesses whether the use of younger matched unrelated donors for allogeneic hematopoietic cell transplantation is associated with better outcomes than the use of older matched sibling donors.

Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):412-419. doi:10.1001/jamaoncol.2021.7008

This cohort study examines a risk stratification model for vertebral compression fracture after stereotactic body radiation therapy.

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019

Abstract Full Text
open access
JAMA Oncol. 2022;8(3):420-444. doi:10.1001/jamaoncol.2021.6987

The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 examines cancer burden and trends globally for 204 countries and territories and by Socio-demographic Index quintiles from 2010 to 2019.

Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

Abstract Full Text
open access online only
JAMA Oncol. 2022;8(3):e216744. doi:10.1001/jamaoncol.2021.6744

This case-control study examines tumors associated with breast cancer susceptibility genes in large-scale population- or hospital-based studies.

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts

Abstract Full Text
open access online only
JAMA Oncol. 2022;8(3):e216871. doi:10.1001/jamaoncol.2021.6871

This cohort study explores associations between the duration of androgen deprivation therapy and distant metastasis-free survival in men undergoing external beam radiotherapy with and without a brachytherapy boost for treatment of high-risk prostate cancer.

Brief Report

Geospatial Disparities in the Treatment of Curable Breast Cancer Across the US

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):445-449. doi:10.1001/jamaoncol.2021.7337

This cohort study assesses the extent to which geospatial variation in initial breast cancer care is associated with region vs patient factors.

Research Letter

Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):477-479. doi:10.1001/jamaoncol.2021.7015

This secondary analysis reports the survival outcome in patients with EGFR variant-positive non–small-cell lung cancer who had a body mass index that was higher or lower than 24.

Review

Radiofrequency Radiation and Cancer: A Review

Abstract Full Text
JAMA Oncol. 2022;8(3):456-461. doi:10.1001/jamaoncol.2021.5964

This review considers radiofrequency radiation and potential biophysical mechanisms of cancer induction and discusses the existent epidemiological evidence in humans and laboratory animals.

Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2022;8(3):462-473. doi:10.1001/jamaoncol.2021.5970

This narrative review provides an overview of chemotherapy and targeted therapies effective at enhancing human leukocyte antigen class I antigen-processing machinery component expression and function in cancer cells and their treatment synergy with immune checkpoint inhibitors.

Viewpoint

Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers: Let's Not Forget Radiotherapy

Abstract Full Text
JAMA Oncol. 2022;8(3):333-334. doi:10.1001/jamaoncol.2021.6641

This viewpoint discusses the use of radiotherapy and immunotherapy together to treat resectable intrathoractic cancers.

Accelerated Approval Is Not Conditional Approval: Insights From International Expedited Approval Programs

Abstract Full Text
JAMA Oncol. 2022;8(3):335-336. doi:10.1001/jamaoncol.2021.6854

This Viewpoint compares the US Food and Drug Administration’s accelerated approval pathway for drugs and biologics with similar programs developed by other international regulatory health authorities.

Measuring the Effect of Local Control From Radiotherapy in Patients With Pancreatic Adenocarcinoma

Abstract Full Text
JAMA Oncol. 2022;8(3):337-338. doi:10.1001/jamaoncol.2021.7037

This Viewpoint discusses whether the addition of radiation therapy to surgery and chemotherapy affords additional local control translating to a survival advantage in patients with pancreatic cancer.

Editorial

Antibiotic Prophylaxis of Surgical Site Infections—A Double-edged Sword for Oncology Patients?

Abstract Full Text
JAMA Oncol. 2022;8(3):340-342. doi:10.1001/jamaoncol.2021.6619

Genetic Ancestry and Childhood Acute Lymphoblastic Leukemia Subtypes and Outcomes in the Genomic Era

Abstract Full Text
JAMA Oncol. 2022;8(3):342-343. doi:10.1001/jamaoncol.2021.6785
Invited Commentary

Decreasing the Dose and Volume of Elective Nodal Radiotherapy in HPV-Associated Oropharyngeal Cancer: How Low Can We Go?

Abstract Full Text
JAMA Oncol. 2022;8(3):372-373. doi:10.1001/jamaoncol.2021.6411

New 2021 USPSTF Lung Cancer Screening Criteria—An Opportunity to Mitigate Racial Disparity

Abstract Full Text
JAMA Oncol. 2022;8(3):383-384. doi:10.1001/jamaoncol.2021.6708

Analysis of Routine Computed Tomographic Scans With Radiomics and Machine Learning: One Step Closer to Clinical Practice

Abstract Full Text
JAMA Oncol. 2022;8(3):393-394. doi:10.1001/jamaoncol.2021.6768
Cancer Care Chronicles

Little Things

Abstract Full Text
JAMA Oncol. 2022;8(3):339. doi:10.1001/jamaoncol.2021.6652

This essay describes the author’s experience treating a patient with cancer and a tracheostomy who used fingerpainting to tell her story of hope and resilience.

Poetry and Oncology

RCT

Abstract Full Text
JAMA Oncol. 2022;8(3):487. doi:10.1001/jamaoncol.2021.6110
Comment & Response

Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials

Abstract Full Text
JAMA Oncol. 2022;8(3):479-480. doi:10.1001/jamaoncol.2021.6968

Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply

Abstract Full Text
JAMA Oncol. 2022;8(3):480. doi:10.1001/jamaoncol.2021.6971

Hypofractionated Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer—Does Size Matter?

Abstract Full Text
JAMA Oncol. 2022;8(3):480-481. doi:10.1001/jamaoncol.2021.7157

Hypofractionated Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer—Does Size Matter?—Reply

Abstract Full Text
JAMA Oncol. 2022;8(3):481. doi:10.1001/jamaoncol.2021.7160

Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy

Abstract Full Text
JAMA Oncol. 2022;8(3):481-482. doi:10.1001/jamaoncol.2021.7163

Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy—Reply

Abstract Full Text
JAMA Oncol. 2022;8(3):482-483. doi:10.1001/jamaoncol.2021.7166

Concerns About Methods Used in Modeling Study of Risk-Stratified Screening for Breast Cancer

Abstract Full Text
JAMA Oncol. 2022;8(3):483-484. doi:10.1001/jamaoncol.2021.7311
Correction

Errors in the Calculation Used to Estimate Number of Overdiagnoses in Study of Risk-Stratified Screening for Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):484. doi:10.1001/jamaoncol.2021.7316

Changes Reflecting Corrections to Related Article

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):484. doi:10.1001/jamaoncol.2021.7317

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):484. doi:10.1001/jamaoncol.2022.0283
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2022;8(3):326. doi:10.1001/jamaoncol.2021.5486
×